Gastrointestinal Cancer

In this fourth episode of OncChats: Understanding Endoscopy in the Realm of GI Cancers, Madappa Kundranda, MD, PhD, and Toufic A. Kachaamy, MD, provide insight on the use of endoscopic submucosal resection and endoscopic evaluation for tumor response as it pertains to organ preservation in gastrointestinal cancer.

Jimmy Hwang, MD, discusses findings supporting the use of immunotherapy in hepatocellular carcinoma and biliary tract cancer, the potential benefits of antibody-drug conjugates in metastatic colorectal cancer, and unmet needs in esophageal squamous cell carcinoma and rectal cancer.

The addition of zolbetuximab to CAPOX led to a statistically significant improvement in progression-free survival and overall survival compared with placebo plus CAPOX for patients with Claudin-18.2–positive/HER2-negative, unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

Closing out their discussion on biliary tract cancers, expert panelists share key takeaways and excitement for the evolving treatment paradigm.

Comprehensive insight on novel targeted agents under investigation in the setting of biliary tract cancers.

Investigators are unclear about the factors driving the explosive growth in incidence of appendiceal cancer over the past 2 decades.

Ripretinib has been added to the National Comprehensive Cancer Network Guidelines as a preferred regimen in the second-line treatment of patients with gastrointestinal stromal tumor who are intolerant to sunitinib.

The FDA has placed a clinical hold on a phase 1 trial investigating the antibody-drug conjugate XMT-2056 for the treatment of patients with advanced/recurrent solid tumors that express HER2.

The combination of AB011 and capecitabine/oxaliplatin was found to have a manageable safety profile and to showcase early clinical benefit when used as first-line treatment in patients with gastric cancer or gastroesophageal junction adenocarcinoma.

Panelists share real-world evidence involving the use of lenvatinib in advanced HCC.

A panel of oncologists review a patient profile, evaluating a patient with advanced HCC treated with lenvatinib.

Zev A. Wainberg, MD, discusses the rationale behind the phase 3 NAPOLI 3 trial in patients with metastatic pancreatic ductal adenocarcinoma.

Key opinion leaders in the field of biliary tract cancers highlight mainstay systemic therapy regimens within the treatment paradigm.

A brief discussion on the continued role of liver transplant in biliary tract cancers and when it is appropriate to consider a patient for this procedure.

Daniel H. Ahn, DO, discusses the evolution of first-line treatments in advanced hepatocellular carcinoma.

Daniel H. Ahn, DO, discusses the importance of drug toxicity when selecting between first-line immune checkpoint inhibitor–based regimens in hepatocellular carcinoma.

Expert oncologists analyze immunotherapy-based combinations in the frontline setting for patients with hepatocellular carcinoma.

Experts discuss the factors they take into consideration when selecting the appropriate treatment in advanced HCC.

A comprehensive review of liver-directed therapies available to aid in the management of biliary tract cancers.

Moving on to identify specific treatment modalities, panelists discuss the surgical and perioperative strategies used to manage biliary tract cancers.

The FDA has granted an orphan drug designation to the CEACAM1/5 antibody YB-200 for the treatment of patients with hepatocellular carcinoma.

Novel treatment options are needed in neuroendocrine tumors, and advances in immunotherapy have not been optimized in this population.

Eric Van Cutsem, MD, PhD, discusses primary efficacy and safety findings from the phase 3 SPOTLIGHT and GLOW trials investigating the monoclonal antibody zolbetuximab in metastatic gastric cancer.

The National Medical Products Administration of China has granted approval to tislelizumab in combination with fluoropyrimidine and platinum chemotherapy in the frontline treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with a high PD-L1 expression.

James Harding, MD, discusses future directions in the treatment of patients with advanced biliary tract cancer.